Brazil's covid-19 guidelines: political hijack of public health
the lancet; 399 (10331), 2022
Ano de publicação: 2022
On Jan 20, 2022, in an unprecedented
move, the Brazilian Secretary for
Science, Technology, and Innovation
overrode the Brazilian guideline for
COVID-19 outpatient treatment. The
guideline was originally demanded
by the Ministry of Health, developed
by a team of academics, specialists,
and health technology analysts,
according to GRADE-ADOLOPMENT
methodology.1
The guideline, which
recommended against the use of
drugs without scientific proof of
efficacy, such as hydroxychloroquine and ivermectin,2
was finally
approved by the National Committee
for Health Technology Incorporation
(CONITEC) in December, 2021. In
the Brazilian public health system,
CONITEC has a central role in evaluating
and recommending technology
implementation on the basis of
the scientific paradigms of efficacy,
effectiveness, and cost-effectiveness.